These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

634 related articles for article (PubMed ID: 31233199)

  • 1. Matrine improves skeletal muscle atrophy by inhibiting E3 ubiquitin ligases and activating the Akt/mTOR/FoxO3α signaling pathway in C2C12 myotubes and mice.
    Chen L; Chen L; Wan L; Huo Y; Huang J; Li J; Lu J; Xin B; Yang Q; Guo C
    Oncol Rep; 2019 Aug; 42(2):479-494. PubMed ID: 31233199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cryptotanshinone prevents muscle wasting in CT26-induced cancer cachexia through inhibiting STAT3 signaling pathway.
    Chen L; Yang Q; Zhang H; Wan L; Xin B; Cao Y; Zhang J; Guo C
    J Ethnopharmacol; 2020 Oct; 260():113066. PubMed ID: 32505837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Valproic acid attenuates skeletal muscle wasting by inhibiting C/EBPβ-regulated atrogin1 expression in cancer cachexia.
    Sun R; Zhang S; Hu W; Lu X; Lou N; Yang Z; Chen S; Zhang X; Yang H
    Am J Physiol Cell Physiol; 2016 Jul; 311(1):C101-15. PubMed ID: 27122162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paeoniflorin alleviated muscle atrophy in cancer cachexia through inhibiting TLR4/NF-κB signaling and activating AKT/mTOR signaling.
    Zhu Z; Li C; Gu X; Wang X; Zhang G; Fan M; Zhao Y; Liu X; Zhang X
    Toxicol Appl Pharmacol; 2024 Mar; 484():116846. PubMed ID: 38331105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Muscle-specific E3 ubiquitin ligases are involved in muscle atrophy of cancer cachexia: an in vitro and in vivo study.
    Yuan L; Han J; Meng Q; Xi Q; Zhuang Q; Jiang Y; Han Y; Zhang B; Fang J; Wu G
    Oncol Rep; 2015 May; 33(5):2261-8. PubMed ID: 25760630
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Lee HY; Lee J; Lim H; Kim HY; Koo YS; Lim JS; Yoon Y
    J Med Food; 2024 May; 27(5):385-395. PubMed ID: 38574296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resveratrol prevents TNF-α-induced muscle atrophy via regulation of Akt/mTOR/FoxO1 signaling in C2C12 myotubes.
    Wang DT; Yin Y; Yang YJ; Lv PJ; Shi Y; Lu L; Wei LB
    Int Immunopharmacol; 2014 Apr; 19(2):206-13. PubMed ID: 24534773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imoxin prevents dexamethasone-induced promotion of muscle-specific E3 ubiquitin ligases and stimulates anabolic signaling in C2C12 myotubes.
    Eo H; Reed CH; Valentine RJ
    Biomed Pharmacother; 2020 Aug; 128():110238. PubMed ID: 32450522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iron-induced skeletal muscle atrophy involves an Akt-forkhead box O3-E3 ubiquitin ligase-dependent pathway.
    Ikeda Y; Imao M; Satoh A; Watanabe H; Hamano H; Horinouchi Y; Izawa-Ishizawa Y; Kihira Y; Miyamoto L; Ishizawa K; Tsuchiya K; Tamaki T
    J Trace Elem Med Biol; 2016 May; 35():66-76. PubMed ID: 27049128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selumetinib Attenuates Skeletal Muscle Wasting in Murine Cachexia Model through ERK Inhibition and AKT Activation.
    Quan-Jun Y; Yan H; Yong-Long H; Li-Li W; Jie L; Jin-Lu H; Jin L; Peng-Guo C; Run G; Cheng G
    Mol Cancer Ther; 2017 Feb; 16(2):334-343. PubMed ID: 27599525
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Lee MK; Choi YH; Nam TJ
    Mol Med Rep; 2021 Jul; 24(1):. PubMed ID: 33955507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 20(s)‑ginseonside‑Rg3 modulation of AMPK/FoxO3 signaling to attenuate mitochondrial dysfunction in a dexamethasone‑injured C2C12 myotube‑based model of skeletal atrophy
    Wang M; Jiang R; Liu J; Xu X; Sun G; Zhao D; Sun L
    Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33649814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective Effect of
    Lee MK; Choi JW; Choi YH; Nam TJ
    Mar Drugs; 2019 May; 17(5):. PubMed ID: 31083497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monotropein Improves Dexamethasone-Induced Muscle Atrophy via the AKT/mTOR/FOXO3a Signaling Pathways.
    Wang P; Kang SY; Kim SJ; Park YK; Jung HW
    Nutrients; 2022 Apr; 14(9):. PubMed ID: 35565825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Compound Z526 alleviates chemotherapy-induced cachectic muscle loss by ameliorating oxidative stress-driven protein metabolic imbalance and apoptosis.
    Gu X; Lu S; Fan M; Xu S; Lin G; Zhao Y; Zhao W; Liu X; Dong X; Zhang X
    Eur J Pharmacol; 2024 Jul; 974():176538. PubMed ID: 38552940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Group I Paks support muscle regeneration and counteract cancer-associated muscle atrophy.
    Cerquone Perpetuini A; Re Cecconi AD; Chiappa M; Martinelli GB; Fuoco C; Desiderio G; Castagnoli L; Gargioli C; Piccirillo R; Cesareni G
    J Cachexia Sarcopenia Muscle; 2018 Aug; 9(4):727-746. PubMed ID: 29781585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size.
    Trendelenburg AU; Meyer A; Rohner D; Boyle J; Hatakeyama S; Glass DJ
    Am J Physiol Cell Physiol; 2009 Jun; 296(6):C1258-70. PubMed ID: 19357233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Des-acyl ghrelin exhibits pro-anabolic and anti-catabolic effects on C2C12 myotubes exposed to cytokines and reduces burn-induced muscle proteolysis in rats.
    Sheriff S; Kadeer N; Joshi R; Friend LA; James JH; Balasubramaniam A
    Mol Cell Endocrinol; 2012 Apr; 351(2):286-95. PubMed ID: 22266196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Forkhead box O3 plays a role in skeletal muscle atrophy through expression of E3 ubiquitin ligases MuRF-1 and atrogin-1 in Cushing's syndrome.
    Kang SH; Lee HA; Kim M; Lee E; Sohn UD; Kim I
    Am J Physiol Endocrinol Metab; 2017 Jun; 312(6):E495-E507. PubMed ID: 28246104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carnosol analogue WK-63 alleviated cancer cachexia by inhibiting NF-κB and activating AKT pathways in muscle while inhibiting NF-κB and AMPK pathways in adipocyte.
    Pan X; Zhang G; Wei K; Gu X; Dan J; Zhao Y; Liu X; Cheng C; Zhang X
    Toxicol Appl Pharmacol; 2023 Nov; 479():116729. PubMed ID: 37863360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.